What is Uterine Carcinosarcoma (MMMT)

Uterine carcinosarcoma (MMMT) is a rare, aggressive form of uterine cancer that contains both carcinomatous (epithelial) and sarcomatous (connective tissue) elements. Because it behaves similarly to high-grade uterine cancer, it is typically managed as a high-risk malignancy requiring specialized oncological care.

What exactly is Uterine Carcinosarcoma (MMMT)?

Uterine carcinosarcoma, formerly known as Malignant Mixed Müllerian Tumor (MMMT), is a rare diagnosis that accounts for approximately 2% to 5% of all uterine cancers. Unlike typical endometrial cancers, Uterine Carcinosarcoma (MMMT) is categorized by the presence of two distinct types of cancer cells within the same tumor. This dual nature makes the disease clinically aggressive, with a higher propensity for recurrence and spread compared to more common types of endometrial adenocarcinoma.

Who is typically affected by Uterine Carcinosarcoma (MMMT)?

Uterine Carcinosarcoma (MMMT) most frequently affects postmenopausal women, with the average age of diagnosis being between 65 and 70 years old. While the exact cause remains under investigation, researchers believe the tumor arises from a single precursor cell that differentiates into two distinct cell lines. Risk factors often overlap with those of other uterine cancers, including obesity, nulliparity (not having given birth), and late menopause.

What distinguishes Uterine Carcinosarcoma (MMMT) from other cancers?

The primary difference lies in the aggressive biological behavior of Uterine Carcinosarcoma (MMMT) compared to typical endometrial cancer. Key clinical features include:

• Dual-Component Histology: The coexistence of epithelial (carcinoma) and mesenchymal (sarcoma) tissue.


• Higher Recurrence Rate: It is significantly more likely to spread to lymph nodes or distant organs (like the lungs or liver) early in the disease progression.


• Aggressive Staging: Because Uterine Carcinosarcoma (MMMT) is often advanced at the time of diagnosis, it requires a multimodal treatment approach.

Next steps

• Consult with a gynecologic oncologist who has specific experience treating rare uterine sarcomas.


• Connect with the 31 members of our DiseaseMaps.org community to share experiences and find peer support.


• Discuss clinical trial participation with your care team to access the latest targeted therapies or immunotherapies.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• National Cancer Institute (NCI) – Rare Uterine Cancers Overview


• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Database of Rare Diseases and Orphan Drugs


• Society of Gynecologic Oncology (SGO) Clinical Guidelines